Photodynamic therapy for polypoidal choroidal vasculopathy.

作者信息

Kumar Chhablani Jay

出版信息

Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):791; author reply 793. doi: 10.1007/s00417-010-1478-7. Epub 2010 Aug 6.

DOI:10.1007/s00417-010-1478-7

PMID:20689963

Abstract

摘要

相似文献

Photodynamic therapy for polypoidal choroidal vasculopathy.

Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):791; author reply 793. doi: 10.1007/s00417-010-1478-7. Epub 2010 Aug 6.

Reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.

Am J Ophthalmol. 2010 Sep;150(3):443-4; author reply 444. doi: 10.1016/j.ajo.2010.05.033.

Clinical features and follow-up results of pulsating polypoidal choroidal vasculopathy treated with photodynamic therapy.

Acta Ophthalmol. 2010 Sep;88(6):660-8. doi: 10.1111/j.1755-3768.2009.01517.x.

Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.

Retina. 2011 Jul-Aug;31(7):1287-93. doi: 10.1097/IAE.0b013e3182003ccd.

Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Am J Ophthalmol. 2010 Jul;150(1):48-54.e1. doi: 10.1016/j.ajo.2010.02.008.

Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.

Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1233-9. doi: 10.1007/s00417-010-1365-2. Epub 2010 Mar 30.

Photodynamic therapy for polypoidal choroidal vasculopathy.

Am J Ophthalmol. 2010 Nov;150(5):754-5; author reply 755. doi: 10.1016/j.ajo.2010.07.021.

Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation.

Retina. 2011 Sep;31(8):1589-97. doi: 10.1097/IAE.0b013e31820f4b21.

Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up.

Retina. 2010 Sep;30(8):1197-205. doi: 10.1097/IAE.0b013e3181d37486.

One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.

Ophthalmologica. 2011;226(3):119-26. doi: 10.1159/000329466. Epub 2011 Jul 13.

引用本文的文献

Visual Parameters and Retinal Morphology for Polypoidal Choroidal Vasculopathy Pre- and Post-Intravitreal Ranibizumab with or without Photodynamic Therapy: A Short-Term Prospective Study.

Int J Environ Res Public Health. 2021 Mar 4;18(5):2581. doi: 10.3390/ijerph18052581.

Patient-Perceived Benefit of Treatment in Polypoidal Choroidal Vasculopathy: A Pilot Study.

Int J Environ Res Public Health. 2020 Sep 2;17(17):6378. doi: 10.3390/ijerph17176378.

Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration.

Biomed Res Int. 2018 Feb 26;2018:9640131. doi: 10.1155/2018/9640131. eCollection 2018.

本文引用的文献

Intravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: visual acuity after 1 year of follow-up.

Retina. 2010 Apr;30(4):548-54. doi: 10.1097/IAE.0b013e3181bcf1b8.

Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.

Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1233-9. doi: 10.1007/s00417-010-1365-2. Epub 2010 Mar 30.

Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results.

Br J Ophthalmol. 2010 Mar;94(3):297-301. doi: 10.1136/bjo.2008.150029. Epub 2009 Sep 1.

Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy.

Ophthalmic Surg Lasers Imaging. 2009 May-Jun;40(3):300-3. doi: 10.3928/15428877-20090430-14.

The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy.

Korean J Ophthalmol. 2008 Jun;22(2):92-9. doi: 10.3341/kjo.2008.22.2.92.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验